A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Launched by BRISTOL-MYERS SQUIBB · Feb 7, 2023
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
- • Body mass index 18 to 40 kg/m\^2 and total body weight \> 50 kg (110 lbs)
- • Deemed by Investigator to be eligible for phototherapy or systemic therapy
- • Psoriatic plaques must cover ≥ 10% of body surface area at baseline
- • Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline
- Exclusion Criteria:
- • Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
- • Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
- • Any significant acute or chronic medical illness
- • Other protocol-defined inclusion/exclusion criteria apply
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Itabashi, Tokyo, Japan
Cleveland, Ohio, United States
Fremont, California, United States
Cleveland, Ohio, United States
Brisbane, Queensland, Australia
Carlton, Victoria, Australia
Fukuoka Shi, , Japan
Coral Gables, Florida, United States
Hamilton, Ontario, Canada
Nagoya Shi, , Japan
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Encinitas, California, United States
Encino, California, United States
Fountain Valley, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Santa Ana, California, United States
Coral Gables, Florida, United States
Ocala, Florida, United States
Clarksville, Indiana, United States
Beverly, Massachusetts, United States
Portsmouth, New Hampshire, United States
Greenville, South Carolina, United States
Webster, Texas, United States
Spokane, Washington, United States
Brisbane, Queensland, Australia
Carlton, Victoria, Australia
Pascoe Vale South, Victoria, Australia
Barrie, Ontario, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
Richmond Hill, Ontario, Canada
Toronto, Ontario, Canada
Novy Jicin, Cz, Czechia
Ostrava, Mo, Czechia
Prague, , Czechia
Praha 1, , Czechia
Reims, Marne, France
Martigues, , France
Rouen, , France
Saint Priest En Jarez, , France
Toulon, , France
Sapporo Shi, Hokkaido, Japan
Fukuoka Shi, , Japan
Itabashi Ku, , Japan
Itabashi Ku, , Japan
Nagoya Shi, , Japan
Tsu City, , Japan
Wroclaw, Ds, Poland
Lodz, Ld, Poland
Lodz, Ld, Poland
Warszawa, Mz, Poland
Warszawa, Mz, Poland
Warszawa, Mz, Poland
Lodz, , Poland
Wroclaw, , Poland
Barcelona, , Spain
Hinckley, Lec, United Kingdom
Leytonstone, Lnd, United Kingdom
Liverpool, Merseyside, United Kingdom
Durham, North Carolina, United States
London, Lnd, United Kingdom
Los Angeles, California, United States
Beverly, Massachusetts, United States
Coral Gables, Florida, United States
Durham, North Carolina, United States
Sapporo Shi, Hokkaido, Japan
Itabashi Ku, Tokyo, Japan
Prague, , Czechia
Wroclaw, Ds, Poland
Encino, California, United States
Skokie, Illinois, United States
Hinckley, , United Kingdom
Leawood, Kansas, United States
Metairie, Louisiana, United States
Lee's Summit, Missouri, United States
Rapid City, South Dakota, United States
Dallas, Texas, United States
Prague, , Czechia
St. John's, Newfoundland And Labrador, Canada
Itabashi, Tokyo, Japan
Phoenix, Arizona, United States
Barrie, Ontario, Canada
London, Ontario, Canada
Sapporo Shi, Hokkaido, Japan
Hinckley, Lec, United Kingdom
Leytonstone, Lnd, United Kingdom
Webster, Texas, United States
Birmingham, Alabama, United States
Encino, California, United States
Fountain Valley, California, United States
Fremont, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Santa Ana, California, United States
Coral Gables, Florida, United States
Skokie, Illinois, United States
Clarksville, Indiana, United States
Leawood, Kansas, United States
Beverly, Massachusetts, United States
Lee's Summit, Missouri, United States
Portsmouth, New Hampshire, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Rapid City, South Dakota, United States
Dallas, Texas, United States
Webster, Texas, United States
Leytonstone, , United Kingdom
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials